Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives
@article{Federico2012GemcitabineloadedLR,
title={Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives},
author={Cinzia Federico and Valeria Maria Morittu and Domenico Britti and Elena Trapasso and Donato Cosco},
journal={International Journal of Nanomedicine},
year={2012},
volume={7},
pages={5423 - 5436},
url={https://api.semanticscholar.org/CorpusID:12193515}
}This review describes the strategies used in recent years to improve the biopharmaceutical properties of gemcitabine, a nucleoside analog deoxycytidine antimetabolite characterized by activity…
Figures from this paper
49 Citations
Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy
- 2022
Medicine, Materials Science
Assessment of gemcitabine hydrochloride-based nanotherapeutics in cancer: a proof of concept study
- 2023
Medicine, Materials Science
Gemcitabine is examined not as a specific drug, but as a proof of concept study that has drawn upon a wide range of innovative nanotechnology approaches, particularly for the treatment of cancer.
Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells
- 2014
Medicine
A novel passive loading approach named Small Volume Incubation method (SVI) was developed and compared to the reverse phase evaporation (REV) and remote loading methods and showed significant improvement in cytotoxicity to the gemcitabine-resistant pancreatic cancer cell lines.
Development of Liposomal Gemcitabine with High Drug Loading Capacity.
- 2019
Medicine
This study shows that bioactive liposomal Gem with high drug loading capacity can be produced by remote loading combined with additional approaches to increase drug influx into the liposomes.
Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
- 2019
Medicine
GEM-loaded folic acid receptor-targeted liposomal formulation could be a promising and potential alternative formulation for further development and displayed significantly improved pharmacokinetics, biodistribution profile of loaded GEM.
Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity
- 2020
Medicine
In vivo, the additive cytotoxicity of RGD-GEM-LPs in this study was caused by the presence ofRGD which is more effective in the treatment of breast cancer devoid of toxicity to normal cells.
How can nanomedicines overcome cellular-based anticancer drug resistance?
- 2016
Medicine, Materials Science
This review will specifically focus on the cellular mechanisms involved in the MDR, which will be discussed with respect to the cellular site in which their action is exerted (that is, membrane, cytoplasm or nucleus).
Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
- 2016
Chemistry, Medicine
Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
- 2015
Medicine
The development of an effective LB- MSNP nanocarrier for synergistic PTX/GEM delivery in pancreatic cancer is demonstrated and it is demonstrated that ratiometric PTX incorporation and delivery by the LB-MSNP could suppress CDA expression, contemporaneous with induction of oxidative stress as the operating principle for PTX synergy.
75 References
Gemcitabine-loaded innovative nanocarriers vs GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity
- 2011
Chemistry, Medicine
The use of novel supramolecular vesicular aggregates, polymeric nanoparticles and squalenoylation were treated as interesting innovative approaches for the administration of the nucleoside analog gemcitabine.
Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy
- 2010
Chemistry, Medicine
Cell viability testing on Michigan Cancer Foundation-7 human breast cancer cells evidenced the MDC as having a stronger cytotoxic effect with respect to the active compounds tested in free and liposomal formulations, both as single molecules and in association.
Antibody-modified liposomes for cancer chemotherapy
- 2008
Medicine
This review analyzes the application of antibody-targeted liposomes loaded with various chemotherapeutic agents and various liposomal products under development at experimental and preclinical level to demonstrate high potential for clinical applications.
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
- 2006
Medicine, Materials Science
Stealth liposomes can be actively targeted with monoclonal antibodies or ligands and encapsulating active molecules, with high target efficiency and activity by synthetic modification of the terminal PEG molecule.
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
- 2004
Chemistry, Medicine
Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
- 2010
Chemistry, Medicine
The liposomal GemSQ appears to be a potential delivery system for the effective treatment of tumors and has been investigated on subcutaneous grafted L1210wt leukemia model and compared to that of free gemcitabine.
Novel approaches to deliver gemcitabine to cancers.
- 2008
Chemistry, Medicine
The delivery strategies adopted for gemcitabine led to a considerable improvement in the treatment of cancers at the preclinical stage, and some of them are potential candidates for clinical trials.
In Vitro Evaluation of the Activity of Gemcitabine-Loaded Pegylated Unilamellar Liposomes Against Papillary Thyroid Cancer Cells
- 2010
Medicine
The advantage of channeling gemcitabine by liposomes is demonstrated, suggesting a promising role for such a pharmaceutical formulation in the treatment of refractory papillary thyroid carcinoma.